ArticleBMC nephrology2025
Early relapse during B lymphocyte depletion of children with frequently relapse /steroid dependent nephrotic syndrome after rituximab treatment.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with frequent relapsing or steroid-dependent nephrotic syndrome (FRSDNS) often maintain remission during the period of B lymphocyte depletion following rituximab (RTX) administration. However, a subset of patients may experience early relapse and subsequently develop refractory disease. In this retrospective study, we summarized the clinical characteristics and outcomes of patients who experienced early relapse during B lymphocyte depletion.
methodsThis was a retrospective cohort study. The relapse group included six FRSDNS cases with early relapse during B lymphocyte depletion, while the control group consisted of 15 patients without relapse. A comparative analysis was performed on the clinical characteristics and follow-up outcomes of the two groups.
resultsCompared with the control group, the relapse group exhibited a higher proportion of elevated CD4 + T cell levels (100% vs. 47%, P = 0.046) and lower doses glucocorticoid administration (83.3% vs. 26.7%, P = 0.046) at baseline. Following RTX injection, patients in the control group maintained remission within six months, and the number of relapses within the first year was higher in the relapse group than in the control group. [1.5 (1, 2.5) vs. 0 (0, 0)], Z= -3.708, P = 0.000)].
conclusionEarly-stage relapses were predominantly observed in patients who received lower doses glucocorticoids or had higher CD4 + lymphocyte levels at baseline. Patients experiencing early relapse demonstrated lower overall efficacy with RTX treatment. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.